Oral Medications
Enterprise Technology Solutions Buffered Aspirin Tablet
Genuine Buffered Aspirin (NSAID) Tablet 2 Tablets/Packet 30 Packetss/Box
Cayman Chemical -Ibuprofen-d3sodIum salt 5mg
An active metabolite of brinzolamide inhibits CAII and CAIV activities (IC50s 1 28 and 128 nM respectively)
Cayman Chemical -2-hydroxy Ibuprofen 5mg
An inhibitor of CK1a CK1 and CK1ε (IC50s 8.9 0.5 and 4.7 M respectively) reduces immunoprecipitation of CK1a CK1 and CK1ε from HCT116 cell lysates in a concentration-dependent manner induces reprogramming of mEpiSCs into ESCs
Cayman Chemical Thromboxn B2 AChE TrACr 100dtn
An analytical reference standard categorized as a cathinone provided as an exempt preparation intended for research and forensic applications
Cayman Chemical Fluprostenol AChE TrACr 100dtn
A 2-opioid receptor inverse agonist (Ki 0.013 nM in CHO-DG44 cells expressing the mouse receptor) selective for 2-opioid receptors over K- and -opioid receptors (Kis 13 and 12 nM in PC12 and COS-7 cells expressing the mouse and rat receptors respectively) induces axonal retraction in primary mouse hippocampal neurons under both normoxic and hypoxic conditions at 1 and 10 UM an activator of TRPM7 induces calcium influx in HEK293 cells expressing mouse TRPM7 (EC50 20.7 UM) reduces self-administration of alcohol or alcohol mixed with saccharin or quinine in alcohol-preferring rats at 6 mg/kg
Cayman Chemical ProstaglndIn Screeng AChE
A PTH1R agonist selectively induces cAMP production in COS-7 cells expressing human PTH1R (EC50 2.4 UM) over COS-7 cells expressing human PTH2R (EC50 100 UM) induces calcium release from isolated fetal rat long bones at 1 and 3 UM increases lumbar spine and proximal femur BMD lumbar spine bone strength serum levels of osteocalcin and bone formation in the lumbar spine without affecting serum calcium levels in an OVX rat model of osteopenia at 10 mg/kg per day increases serum but not urinary calcium levels in a TPTX rat model of hypothyroidism at 9 mg/kg
Cayman Chemical ProstaglndIn D2 ExprS AChE
A cucurbitane glycoside with anti-inflammatory activity inhibits LPS-induced secretion of IL-1B IL-6 and TNF-a from as well as LPS-induced increases in TLR4 levels in RAW 264.7 macrophages at 50 UM reduces increases in BALF levels of IL-1B IL-6 and TNF-a and increases in lung tissue Mpo activity in a mouse model of LPS-induced acute lung injury at 20 mg/kg decreases lung fibrosis and inflammation as well as increases animal survival and reduced lung levels of MMP-9 in a mouse model of bleomycin-induced pulmonary fibrosis at 20 mg/kg per day
Cayman Chemical ProstaglndIn F2a AChE TrACr
A PROTAC that drives hexokinase 2 degradation induces degradation of hexokinase 2 in 786-O and PANC-1 cells at 20 UM cytotoxic to 786-O 4T1 PANC-1 HGC-27 and MCF-7 cancer cells (IC50s 34.07 5.08 31.53 6.11 and 21.65 UM respectively) reduces ECAR and OCR in 4T1 cells at 20 UM reduces tumor volume and induces intratumoral cytokine accumulation and pyroptosis in a 4T1 murine mammary carcinoma model at 50 mg/kg
Cayman Chemical 6keto ProstaglndIn F1a AChE
An active metabolite of (S)-duloxetine inhibits SERT NET and DAT in lipid membranes (Kis 266 920 and 2814 nM respectively for the human transporters)
Cayman Chemical -2-hydroxy Ibuprofen 1mg
An inhibitor of CK1a CK1 and CK1ε (IC50s 8.9 0.5 and 4.7 M respectively) reduces immunoprecipitation of CK1a CK1 and CK1ε from HCT116 cell lysates in a concentration-dependent manner induces reprogramming of mEpiSCs into ESCs
Cayman Chemical -Ibuprofen-d3 50mg
An irreversible dual inhibitor of EGFR and HER2 (IC50s 34 and 33 nM respectively) inhibits proliferation of A431 SK-BR-3 and SW620 cancer cell lines (IC50s 120 2.5 and 511 nM respectively) suppresses EGFR autophosphorylation and phosphorylation of the downstream effectors AKT and ERK in NCI-H1650 and NCI-H1650(G7) cells inhibits tumor growth in BT474 A431 and SUM190 mouse xenograft models (10 mg/kg)
Cayman Chemical R-Ibuprofen 250mg
A histamine H4 receptor agonist (Kis 5.01 and 14.13 for the human and rat receptors respectively) selective for the rat histamine H4 receptor over the rat histamine H3 receptor (Kis 34.67 and 1778.28 nM respectively) potentiates the formation of HCl-induced ulcers in the rat gastric mucosa at 10 mg/kg an effect that is not blocked by the histamine H4 receptor antagonist JNJ-7777120